CLINICAL TRIALS PROFILE FOR SPARSENTAN
✉ Email this page to a colleague
All Clinical Trials for sparsentan
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01613118 ↗ | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis | Active, not recruiting | Retrophin, Inc. | Phase 2 | 2014-03-01 | This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1), is safe and effective in treating patients with focal segmental glomerulosclerosis (FSGS). |
| NCT01613118 ↗ | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis | Active, not recruiting | Travere Therapeutics, Inc. | Phase 2 | 2014-03-01 | This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1), is safe and effective in treating patients with focal segmental glomerulosclerosis (FSGS). |
| NCT03493685 ↗ | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) | Active, not recruiting | Retrophin, Inc. | Phase 3 | 2018-03-29 | To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS). |
| NCT03493685 ↗ | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) | Active, not recruiting | Travere Therapeutics, Inc. | Phase 3 | 2018-03-29 | To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS). |
| NCT03762850 ↗ | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy | Active, not recruiting | Retrophin, Inc. | Phase 3 | 2018-12-20 | To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN). |
| NCT03762850 ↗ | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy | Active, not recruiting | Travere Therapeutics, Inc. | Phase 3 | 2018-12-20 | To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN). |
| NCT04663204 ↗ | A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy | Recruiting | Travere Therapeutics, Inc. | Phase 2 | 2020-12-10 | To determine the nephroprotective potential of treatment with sparsentan in patients newly-diagnosed with immunoglobulin A nephropathy (IgAN) (ie, incident patients) who have not received prior angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for sparsentan
Condition Name
Clinical Trial Locations for sparsentan
Trials by Country
Clinical Trial Progress for sparsentan
Clinical Trial Phase
Clinical Trial Sponsors for sparsentan
Sponsor Name
